UY26920A1 - 7 - oxo piridopirimidinas - Google Patents

7 - oxo piridopirimidinas

Info

Publication number
UY26920A1
UY26920A1 UY26920A UY26920A UY26920A1 UY 26920 A1 UY26920 A1 UY 26920A1 UY 26920 A UY26920 A UY 26920A UY 26920 A UY26920 A UY 26920A UY 26920 A1 UY26920 A1 UY 26920A1
Authority
UY
Uruguay
Prior art keywords
pyridopirimidin
oxy
treatment
disorders
pro
Prior art date
Application number
UY26920A
Other languages
English (en)
Inventor
D M Goldstein
H B Arzeno
J P Dunn
J J Chen
J A Lim
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26920A1 publication Critical patent/UY26920A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención proporciona compuestos de la fórmula (I) un pro fármaco o una sal aceptable farmacéuticamente del mismo, en donde R1, R2, R3 y Ar1 son aquéllos que se han definido aquí, y los procesos para su preparación y su uso para el tratamiento de trastornos mediados y su uso para el tratamiento de trastornos mediados por p38.
UY26920A 2000-08-31 2001-08-30 7 - oxo piridopirimidinas UY26920A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22957700P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
UY26920A1 true UY26920A1 (es) 2002-02-28

Family

ID=22861834

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26920A UY26920A1 (es) 2000-08-31 2001-08-30 7 - oxo piridopirimidinas

Country Status (18)

Country Link
EP (1) EP1315727B1 (es)
JP (1) JP4146721B2 (es)
KR (1) KR100582325B1 (es)
CN (2) CN1303072C (es)
AR (1) AR033996A1 (es)
AT (1) ATE298751T1 (es)
AU (2) AU1214702A (es)
BR (1) BR0113590A (es)
CA (1) CA2420122A1 (es)
DE (1) DE60111752T2 (es)
ES (1) ES2243568T3 (es)
GT (1) GT200100190A (es)
MX (1) MXPA03001733A (es)
PA (1) PA8527401A1 (es)
PE (1) PE20020524A1 (es)
UY (1) UY26920A1 (es)
WO (1) WO2002018379A2 (es)
ZA (1) ZA200301078B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60315826T2 (de) * 2002-04-19 2008-05-21 Smithkline Beecham Corp. Neue verbindungen
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
CA2539190A1 (en) * 2003-07-07 2005-01-27 George F. Vande Woude Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
JP4968066B2 (ja) * 2005-04-25 2012-07-04 宇部興産株式会社 ４−アミノ−２−アルキルチオ−５−ピリミジンカルバルデヒドの製法
JP2006321749A (ja) * 2005-05-19 2006-11-30 Ube Ind Ltd ２−シアノマロンアルデヒドのアルカリ金属塩の製法
AU2007211684A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
WO2008151992A2 (en) 2007-06-15 2008-12-18 F. Hoffmann-La Roche Ag A novel process for the preparation of 3-amino-pentan-1,5-diol
AU2010303218A1 (en) * 2009-10-09 2012-05-10 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US20120184542A1 (en) 2011-01-19 2012-07-19 Kevin Anderson Pyrido pyrimidines
CA2868156C (en) * 2012-03-22 2020-07-28 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
KR102531596B1 (ko) * 2018-09-14 2023-05-11 아비스코 테라퓨틱스 컴퍼니 리미티드 Fgfr억제제, 그 제조 방법 및 용도
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6183168A (ja) * 1984-09-28 1986-04-26 Ube Ind Ltd ２−メルカプト−４−アミノ−５−ホルミルピリミジンおよびその製法
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2254768A1 (en) * 1996-05-20 1997-11-27 Jinlong Jiang Antagonists of gonadotropin releasing hormone
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP4141830B2 (ja) * 2000-08-31 2008-08-27 エフ．ホフマン−ラ ロシュ アーゲー 細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類

Also Published As

Publication number Publication date
DE60111752T2 (de) 2006-05-04
ZA200301078B (en) 2004-05-07
EP1315727B1 (en) 2005-06-29
ES2243568T3 (es) 2005-12-01
JP4146721B2 (ja) 2008-09-10
KR100582325B1 (ko) 2006-05-22
EP1315727A2 (en) 2003-06-04
AR033996A1 (es) 2004-01-21
WO2002018379A2 (en) 2002-03-07
CN1721412A (zh) 2006-01-18
PE20020524A1 (es) 2002-06-18
JP2004507540A (ja) 2004-03-11
ATE298751T1 (de) 2005-07-15
CN1303072C (zh) 2007-03-07
KR20030022423A (ko) 2003-03-15
BR0113590A (pt) 2003-07-22
CA2420122A1 (en) 2002-03-07
CN1451004A (zh) 2003-10-22
AU2002212147B2 (en) 2007-10-18
DE60111752D1 (de) 2005-08-04
GT200100190A (es) 2002-05-23
AU1214702A (en) 2002-03-13
CN100358892C (zh) 2008-01-02
WO2002018379A3 (en) 2002-07-25
PA8527401A1 (es) 2002-07-30
MXPA03001733A (es) 2003-05-27

Similar Documents

Publication Publication Date Title
UY26920A1 (es) 7 - oxo piridopirimidinas
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
AR035792A1 (es) Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
PA8591701A1 (es) Derivados de pirrolopirimidina
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
PA8547701A1 (es) Nucleosidos 4 substituidos.
CY1107758T1 (el) Πολυμορφα ενος αναλογου εποθεινολης
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
CO4810376A1 (es) Derivados de eritromicina triciclicos
CO5040027A1 (es) Mezclas fungicidas de eteres fenilbencilicos y/o cabamatos con dinitrofenoles, procedimieto para combatir hongos dani- nos con dichas mezclas; utiliacion de dichos compuestos en la preparacion de dichas mezclas y agentes fungicidas for- mulados con d
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
UY27034A1 (es) Derivados de pirimidina
UY27324A1 (es) Nuevas sales de napsilato i

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141001